QTTB vs. ABEO, SLS, PMVP, MIST, RVPH, HOOK, ALLK, ACRS, ETON, and ASRT
Should you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Abeona Therapeutics (ABEO), SELLAS Life Sciences Group (SLS), PMV Pharmaceuticals (PMVP), Milestone Pharmaceuticals (MIST), Reviva Pharmaceuticals (RVPH), Hookipa Pharma (HOOK), Allakos (ALLK), Aclaris Therapeutics (ACRS), Eton Pharmaceuticals (ETON), and Assertio (ASRT). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
Q32 Bio has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Abeona Therapeutics has higher revenue and earnings than Q32 Bio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Abeona Therapeutics had 23 more articles in the media than Q32 Bio. MarketBeat recorded 24 mentions for Abeona Therapeutics and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.79 beat Abeona Therapeutics' score of 0.60 indicating that Q32 Bio is being referred to more favorably in the media.
Q32 Bio's return on equity of -102.52% beat Abeona Therapeutics' return on equity.
Abeona Therapeutics received 511 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 70.27% of users gave Abeona Therapeutics an outperform vote.
Q32 Bio presently has a consensus price target of $47.50, indicating a potential upside of 78.98%. Abeona Therapeutics has a consensus price target of $36.00, indicating a potential upside of 820.72%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Q32 Bio.
Summary
Abeona Therapeutics beats Q32 Bio on 9 of the 16 factors compared between the two stocks.
Get Q32 Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
